NCT01145768View on ClinicalTrials.gov

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Healthy
Interventions
DRUG

TC-5214

4 mg tablet, oral, BID, group 1

DRUG

TC-5214

TBD tablet, oral, BID, groups 2-6

DRUG

Placebo

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY